Cargando…

Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients

Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients’ baseline characteristics. Da...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Bernal, Rosalía, González-Caballero, Juan Luis, Espinosa-Rosso, Raúl, Gómez-Gómez, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206070/
https://www.ncbi.nlm.nih.gov/pubmed/34131191
http://dx.doi.org/10.1038/s41598-021-91912-x
_version_ 1783708568295309312
author Gil-Bernal, Rosalía
González-Caballero, Juan Luis
Espinosa-Rosso, Raúl
Gómez-Gómez, Carmen
author_facet Gil-Bernal, Rosalía
González-Caballero, Juan Luis
Espinosa-Rosso, Raúl
Gómez-Gómez, Carmen
author_sort Gil-Bernal, Rosalía
collection PubMed
description Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients’ baseline characteristics. Data from 250 MS outpatients were collected during the period 1981–2019 from the medical records of the Neurology Service of the HUPM (Hospital Universitario Puerta del Mar)—in Southern Spain—and analysed using Cox models. Neoplasm prevalence was 24%, mainly located on the skin, with cancer prevalence as expected for MS (6.8%). Latency period from MS onset to neoplasm diagnosis was 10.4 ± 6.9 years (median 9.30 [0.9–30.5]). During the observation period β-IFN (70.4% of patients), glatiramer acetate (30.4%), natalizumab (16.8%), fingolimod (24.8%), dimethyl fumarate (24.0%), alemtuzumab (6.0%), and teriflunomide (4.8%) were administered as monotherapy. Change of pattern in step therapy was significantly different in cancer patients vs unaffected individuals (p = 0.011) (29.4% did not receive DMTs [p = 0.000]). Extended Cox model: Smoking (HR = 3.938, CI 95% 1.392–11.140, p = 0.010), being female (HR = 2.006, 1.070–3.760, p = 0.030), and age at MS diagnosis (AGE-DG) (HR = 1.036, 1.012–1.061, p = 0.004) were risk factors for neoplasm development. Secondary progressive MS (SPMS) phenotype (HR = 0.179, 0.042–0.764, p = 0.020) and treatment-time with IFN (HR = 0.923, 0.873–0.977, p = 0.006) or DMF (HR = 0.725, 0.507–1.036, p = 0.077) were protective factors. Tobacco and IFN lost their negative/positive influence as survival time increased. Cox PH model: Tobacco/AGE-DG interaction was a risk factor for cancer (HR = 1.099, 1.001–1.208, p = 0.049), followed by FLM treatment-time (HR = 1.219, 0.979–1.517). In conclusion, smoking, female sex, and AGE-DG were risk factors, and SPMS and IFN treatment-time were protective factors for neoplasm development; smoking/AGE-DG interaction was the main cancer risk factor.
format Online
Article
Text
id pubmed-8206070
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82060702021-06-16 Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients Gil-Bernal, Rosalía González-Caballero, Juan Luis Espinosa-Rosso, Raúl Gómez-Gómez, Carmen Sci Rep Article Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and influence of the patients’ baseline characteristics. Data from 250 MS outpatients were collected during the period 1981–2019 from the medical records of the Neurology Service of the HUPM (Hospital Universitario Puerta del Mar)—in Southern Spain—and analysed using Cox models. Neoplasm prevalence was 24%, mainly located on the skin, with cancer prevalence as expected for MS (6.8%). Latency period from MS onset to neoplasm diagnosis was 10.4 ± 6.9 years (median 9.30 [0.9–30.5]). During the observation period β-IFN (70.4% of patients), glatiramer acetate (30.4%), natalizumab (16.8%), fingolimod (24.8%), dimethyl fumarate (24.0%), alemtuzumab (6.0%), and teriflunomide (4.8%) were administered as monotherapy. Change of pattern in step therapy was significantly different in cancer patients vs unaffected individuals (p = 0.011) (29.4% did not receive DMTs [p = 0.000]). Extended Cox model: Smoking (HR = 3.938, CI 95% 1.392–11.140, p = 0.010), being female (HR = 2.006, 1.070–3.760, p = 0.030), and age at MS diagnosis (AGE-DG) (HR = 1.036, 1.012–1.061, p = 0.004) were risk factors for neoplasm development. Secondary progressive MS (SPMS) phenotype (HR = 0.179, 0.042–0.764, p = 0.020) and treatment-time with IFN (HR = 0.923, 0.873–0.977, p = 0.006) or DMF (HR = 0.725, 0.507–1.036, p = 0.077) were protective factors. Tobacco and IFN lost their negative/positive influence as survival time increased. Cox PH model: Tobacco/AGE-DG interaction was a risk factor for cancer (HR = 1.099, 1.001–1.208, p = 0.049), followed by FLM treatment-time (HR = 1.219, 0.979–1.517). In conclusion, smoking, female sex, and AGE-DG were risk factors, and SPMS and IFN treatment-time were protective factors for neoplasm development; smoking/AGE-DG interaction was the main cancer risk factor. Nature Publishing Group UK 2021-06-15 /pmc/articles/PMC8206070/ /pubmed/34131191 http://dx.doi.org/10.1038/s41598-021-91912-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gil-Bernal, Rosalía
González-Caballero, Juan Luis
Espinosa-Rosso, Raúl
Gómez-Gómez, Carmen
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title_full Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title_fullStr Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title_full_unstemmed Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title_short Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
title_sort potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206070/
https://www.ncbi.nlm.nih.gov/pubmed/34131191
http://dx.doi.org/10.1038/s41598-021-91912-x
work_keys_str_mv AT gilbernalrosalia potentialriskofdiseasemodifyingtherapiesonneoplasmdevelopmentandcoadjutantfactorsinmultiplesclerosisoutpatients
AT gonzalezcaballerojuanluis potentialriskofdiseasemodifyingtherapiesonneoplasmdevelopmentandcoadjutantfactorsinmultiplesclerosisoutpatients
AT espinosarossoraul potentialriskofdiseasemodifyingtherapiesonneoplasmdevelopmentandcoadjutantfactorsinmultiplesclerosisoutpatients
AT gomezgomezcarmen potentialriskofdiseasemodifyingtherapiesonneoplasmdevelopmentandcoadjutantfactorsinmultiplesclerosisoutpatients